{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:22Z","timestamp":1775088022161,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s13555-023-00933-z","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:08Z","timestamp":1684479728000},"page":"1361-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03757013","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Denis","family":"Jullien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Aleth","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Halioua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Derancourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bouloc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"933_CR1","volume-title":"Global report on psoriasis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global report on psoriasis. Geneva: World Health Organization; 2016."},{"key":"933_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583\u201390.","journal-title":"Biochem Pharmacol"},{"key":"933_CR3","unstructured":"Otezla [summary of product characteristics]. Breda, The Netherlands: Amgen Europe B.V.; July 21, 2020.\n Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf."},{"key":"933_CR4","unstructured":"Otezla (apremilast), PDE4 inhibitor immunosuppressant. Brief summary of the transparency committee opinion: Haute Autorite de Sante; 2016 [15 Apr 2016]. Available from: https:\/\/www.has-sante.fr\/jcms\/c_2585408\/en\/otezla-apremilast-pde4-inhibitor-immunosuppressant."},{"key":"933_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","volume":"304","author":"J Feuerhahn","year":"2012","unstructured":"Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304:433\u201341.","journal-title":"Arch Dermatol Res"},{"key":"933_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00403-009-0928-8","volume":"301","author":"M Augustin","year":"2009","unstructured":"Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schafer I, et\u00a0al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301:561\u201371.","journal-title":"Arch Dermatol Res"},{"key":"933_CR7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/jdv.13132","volume":"29","author":"C Chow","year":"2015","unstructured":"Chow C, Simpson MJ, Luger TA, Chubb H, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician\u2019s Global Assessment and Lattice System Physician\u2019s Global Assessment. J Eur Acad Dermatol Venereol. 2015;29:1406\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"933_CR8","first-page":"997","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997\u20131035.","journal-title":"Br J Dermatol"},{"key":"933_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et\u00a0al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"933_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et\u00a0al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80:251-65.e19.","journal-title":"J Am Acad Dermatol"},{"key":"933_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et\u00a0al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"933_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et\u00a0al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"933_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et\u00a0al. The efficacy and safety of apremilast, etanercept, and placebo in patients with moderate to severe plaque psoriasis: 52-week results from a phase 3b, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31:507\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"933_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","volume":"77","author":"J Crowley","year":"2017","unstructured":"Crowley J, Thaci D, Joly P, Peris K, Papp KA, Goncalves J, et\u00a0al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"933_CR15","first-page":"801","volume":"16","author":"B Strober","year":"2017","unstructured":"Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, et\u00a0al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16:801\u20138.","journal-title":"J Drugs Dermatol"},{"key":"933_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Kleyn CE, Conrad C, Sator PG, Stahle M, Eyerich K, et\u00a0al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35:123\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"933_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-021-00628-3","volume":"12","author":"TM Klein","year":"2022","unstructured":"Klein TM, Blome C, Kleyn CE, Conrad C, Sator PG, St\u00e5hle M, et\u00a0al. Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the APPRECIATE study. Dermatol Ther (Heidelb). 2022;12:81\u201395.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"933_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s12325-021-01981-7","volume":"39","author":"PD Ghislain","year":"2022","unstructured":"Ghislain PD, Lambert J, Hoai XL, Hillary T, Roquet-Gravy PP, de la Brassinne M, et\u00a0al. Real-life effectiveness of apremilast for the treatment of psoriasis in Belgium: results from the observational OTELO study. Adv Ther. 2022;39:1068\u201380.","journal-title":"Adv Ther"}],"updated-by":[{"DOI":"10.1007\/s13555-023-00976-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00933-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T03:40:36Z","timestamp":1688787636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00933-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00933-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-023-00976-2","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-023-00976-2","URL":"https:\/\/doi.org\/10.1007\/s13555-023-00976-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}